10-K: Azenta Reports FY25 Income Growth Amid Restructuring, Internal Control Weaknesses

Azenta, Inc. reported a net income from continuing operations of $24.5 million for fiscal year 2025, a significant improvement from a $24.4 million loss in the prior year, despite ongoing internal control weaknesses and a substantial loss from discontinued operations.

Summary

• Net income from continuing operations was $24.5 million for fiscal year 2025, a notable improvement from a net loss of $24.4 million in fiscal year 2024.
• Total revenue increased by 3.6% to $593.8 million in fiscal year 2025, up from $573.4 million in fiscal year 2024, driven by growth in both Sample Management Solutions and Multiomics segments.
• Gross margin improved to 45.5% in fiscal year 2025 from 44.4% in fiscal year 2024, attributed to higher revenue, operational efficiencies, favorable sales mix, and improved cost management.
• Operating expenses decreased in fiscal year 2025 compared to the prior fiscal year, primarily due to lower research and development, selling, general and administrative expenses, and restructuring charges, partially offset by higher transformation costs.
• The company recorded a net loss of $55.8 million for fiscal year 2025, primarily due to an $80.2 million loss from discontinued operations, which includes a $93.1 million estimated loss on assets held for sale related to the B Medical Systems business.
• Identified three material weaknesses in internal control over financial reporting as of September 30, 2025, related to cash flow statement review, account reconciliations, and classification of certain costs.
• A $45.6 million tax benefit was recorded in fiscal year 2025 for a worthless stock deduction on an investment in a foreign subsidiary.
• Repatriated $41.1 million in cash from its China subsidiary during fiscal year 2025, with an additional $21.5 million expected in the next fiscal year.

Sentiment

Score: 4

Explanation: While continuing operations showed improvement in income and gross margin, the overall net loss driven by significant discontinued operations losses and the persistence of multiple material weaknesses in internal controls present substantial concerns. The new lawsuit and ongoing geopolitical risks further weigh on the outlook, indicating a cautious sentiment despite some operational positives.

Positives

• Income from continuing operations significantly improved to $24.5 million in fiscal year 2025, compared to a $24.4 million loss in fiscal year 2024.
• Revenue increased by 3.6% to $593.8 million in fiscal year 2025, showing growth in both Sample Management Solutions and Multiomics segments.
• Gross margin expanded to 45.5% in fiscal year 2025 from 44.4% in fiscal year 2024, driven by operational efficiencies and improved cost management.
• Operating expenses decreased in fiscal year 2025, reflecting successful cost reduction initiatives.
• A $45.6 million tax benefit was recognized in fiscal year 2025 from a worthless stock deduction.
• The company successfully repatriated $41.1 million in cash from its China subsidiary, with plans for an additional $21.5 million.

Negatives

• Despite improved continuing operations, the company reported a net loss of $55.8 million for fiscal year 2025, primarily due to significant losses from discontinued operations.
• Discontinued operations resulted in an $80.2 million net loss in fiscal year 2025, including a $93.1 million estimated loss on assets held for sale for the B Medical Systems business.
• Three material weaknesses in internal control over financial reporting were identified and persist as of September 30, 2025, indicating a lack of effective controls.
• Interest income, net, decreased by $14.1 million in fiscal year 2025 compared to fiscal year 2024, driven by lower interest rates.
• The Multiomics segment experienced a decrease in gross margin by 225 basis points and an increased operating loss of $15.4 million in fiscal year 2025, primarily due to lower revenue for Gene Synthesis and Sanger sequencing services.
• The company is facing a new lawsuit from Edwards Vacuum LLC seeking over $13 million for alleged breaches of representations and warranties related to the 2019 semiconductor cryogenics business sale.

Risks

• Prolonged economic downturns, reductions in government funding for scientific research, increases in interest rates, inflation, public health threats, global climate change, and unfavorable currency exchange rate fluctuations could reduce customer purchases, disrupt operations, increase costs, or lower margins.
• Increased focus on ESG matters (climate change, diversity, ethical supply chains) could raise operating costs, restrict activities, or harm reputation if initiatives fail or are criticized.
• Operating results may fluctuate significantly due to customer demand, product mix, competition, and delays in new product introductions. Failure to introduce new products and services reflecting technological advances could lead to obsolescence.
• If transformation initiatives fail to deliver expected cost savings or efficiencies, financial results could be negatively impacted.
• Exposure to political instability, regulatory changes, corruption, and difficulties in collecting receivables in international markets, particularly with increasing sales in Asia and China.
• Unexpected events (natural disasters, power outages) at facilities or sample storage operations could harm reputation and results, especially given two storage facilities are in a tornado-prone area.
• Inaccurate demand forecasting could lead to excess or obsolete inventory, adversely affecting financial condition.
• Identified material weaknesses in internal control over financial reporting could result in misstatements, harming investor confidence and stock price.
• Impairment of $702.4 million of goodwill and $101.8 million in net intangible assets could adversely affect financial position and results.
• Changes in tax rates or regulations, including the OECD's Pillar Two global minimum tax framework, could affect results of operations and ability to move cash balances.
• Inability to fully utilize net operating loss (NOL) carryforwards due to insufficient profits in relevant jurisdictions (e.g., Luxembourg) could lead to higher effective tax rates.
• Noncompliance with numerous federal, state, local, and foreign regulations (environmental, product design, service offerings, FDA, GLP, export/import) could lead to fines, suspensions, or other penalties.
• Regulations and customer demands related to conflict minerals may increase costs, affect sourcing, and create difficulties in satisfying customers.
• Regulatory risks from potential third-party misuse of synthetic gene products, ethical constraints, and regulatory restrictions on genetic engineering could narrow markets and reduce demand.
• Cybersecurity incidents (breaches, ransomware) could compromise sensitive data and interrupt operations, leading to regulatory penalties and loss of trust. Failure to comply with data protection laws (GDPR, CCPA, My Health My Data Act) could result in enforcement actions, fines, and reputational harm.
• International trade disputes (e.g., US-China friction), tariffs, export controls, and sanctions could disrupt supply chains, increase costs, or limit access to materials. The BIOSECURE Act could impact supply of products and services from Chinese biotechnology companies. The Bulk Transfer Rule restricts cross-border transfers of sensitive personal data to countries of concern, potentially affecting the Genomics segment.
• Ineffective development or deployment of AI technologies could lead to errors, biases, or disruptions. Evolving AI regulations could impose compliance burdens and limit AI use.
• Failure to protect intellectual property could allow competitors to misappropriate technology. Patent expirations could increase competition. Claims of third-party IP infringement could result in costly litigation.
• Failure of key suppliers to deliver components, declines in raw material availability, or underperformance/cybersecurity breaches by external service providers could harm business.
• Customers generally do not make long-term commitments, exposing the company to competitive pressures. Claims for damages to customer materials due to product or service failures could lead to financial liability and reputational harm.
• Stock price volatility, provisions in charter documents and Delaware law that may delay or prevent acquisitions, and securities litigation or stockholder activism could negatively impact share value and operations.

Future Outlook

The company anticipates entering into a definitive agreement to sell its B Medical Systems business by the end of December 2025, aiming to simplify its portfolio and focus on core Sample Management Solutions and Multiomics segments. Remediation plans for identified material weaknesses in internal control over financial reporting are expected to be completed throughout fiscal year 2026. The second phase of the Suzhou, China facility construction is expected to be completed in the second quarter of fiscal year 2026. The company will continue to monitor the financial impact of new U.S. tax laws, including the One Big Beautiful Bill Act, and does not expect them to have a near-term impact on the effective tax rate or cash flows. The company also expects to repatriate an additional $21.5 million from its China subsidiary over the next fiscal year.

Management Comments

• "This strategic action [sale of B Medical Systems] is intended to simplify our portfolio and allow management to focus on driving revenue growth and profitability in our core Sample Management Solutions and Multiomics segments."
• "We believe that our current cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least one year from the date of this Annual Report on Form 10-K and for the foreseeable future thereafter."
• "We are committed to continuing to improve our internal control over financial reporting, and as we continue to evaluate and work to improve our internal control over financial reporting, we may take additional measures to address control deficiencies, or we may modify certain of the remediation measures described above."
• "Our Company Purpose is to enable life sciences organizations around the world to bring impactful therapies to market faster."

Industry Context

Azenta operates in the life sciences industry, providing biological and chemical compound sample exploration and management solutions. The company's focus on sample management and multiomics aligns with the growing importance of sample integrity in biologics, personalized medicine, and cell and gene therapy (CGT) development. The market for genomic services continues to expand, with many companies outsourcing gene sequencing. The company serves a broad customer base including top pharmaceutical and biotechnology companies, research hospitals, and academic institutions. The increasing focus on ESG matters and the rapid evolution of AI technologies are transforming the industry, presenting both opportunities and regulatory challenges for companies like Azenta.

Comparison to Industry Standards

• In the Sample Management Solutions segment, main competitors include Hamilton Company and Liconic AG for automation systems, and Laboratory Corporation of America Holdings and Thermo Fisher Scientific Inc. for storage, consumables and services.
• In the Multiomics segment, main competitors include BGI Genomics Co., Ltd., Eurofins, Scientific S.E., GenScript Biotech Corporation, Integrated DNA Technologies, Inc., Novogene Co., Ltd., and Twist Bioscience Corporation.
• The company's automated stores offer controlled temperature storage down to -80C with the industry's highest throughput of sample retrieval, indicating a competitive advantage in this specific area.
• The company's genomic services offer high quality genetic testing services with fast turnaround times and expert customer support, positioning it as a value-added laboratory services provider.

Management Changes

Corporate Governance

Legal Proceedings

• Edwards Vacuum LLC filed a lawsuit on September 12, 2025, seeking over $13 million for alleged breaches of representations and warranties related to financial information provided during the 2019 sale of the semiconductor cryogenics business (the '2025 Claim'). The company filed a motion to dismiss on October 21, 2025, which is pending.
• The company accrued an additional liability of $0.4 million for the 2020 Claim (indemnification claims from Edwards related to customer warranty claims and inventory) during the three months ended March 31, 2025, resulting in a total accrual of $2.1 million as of September 30, 2025.
• Edwards is seeking recovery from the company for claimed amounts purportedly not covered, or inadequately covered, by representation and warranty insurance related to the 2020 Claim (the 'Claim for Uncovered Amounts').
• The company believes that none of these claims will have a material adverse effect on its consolidated financial condition or results of operations for continuing operations, but an adverse outcome could have a material adverse effect in particular quarterly or annual periods.

Stakeholder Impact

• Shareholders: Potential negative impact from stock price volatility, ongoing material weaknesses in internal controls, and the Edwards Vacuum LLC lawsuit. The expiration of the Politan Cooperation Agreement could introduce uncertainty.
• Employees: Impacted by restructuring initiatives, cost reduction plans, and changes in management. The company emphasizes attracting and retaining diverse talent and fostering employee engagement.
• Customers: Rely on the company for secure sample storage and timely services; disruptions or product failures could lead to claims and reputational harm. Geopolitical tensions and supply chain issues could affect product and service delivery.
• Suppliers/Vendors: Reliance on single-source suppliers and external service providers introduces risks if they fail to perform or suffer cybersecurity breaches.
• Regulatory Authorities: Increased scrutiny due to material weaknesses in internal controls and compliance with evolving data protection and AI regulations.

Next Steps

• Enter into a definitive agreement to sell the B Medical Systems business by the end of December 2025.
• Complete remediation plans for material weaknesses in internal control over financial reporting throughout fiscal year 2026.
• Complete Phase Two construction of the Suzhou, China facility in the second quarter of fiscal year 2026.
• Repatriate an additional $21.5 million in cash from the China subsidiary over the next fiscal year.
• Monitor the financial impact of new U.S. tax laws.
• Receive final audit results for the GENEWIZ tariff matter by the end of the third quarter of fiscal year 2026.
• Continue to develop new product and service offerings and enhance existing ones through research and development.
• Continue to focus on developing processes and technologies that can streamline sample-to-data workflows.
• Address the lawsuit filed by Edwards Vacuum LLC seeking over $13 million.

Key Dates

Recommendation

Azenta's fiscal year 2025 results show a positive shift in continuing operations, with revenue growth and improved gross margins, indicating some success in its strategic focus on life sciences. However, the substantial net loss driven by discontinued operations, coupled with the persistence of three material weaknesses in internal control over financial reporting, introduces significant uncertainty and risk. The ongoing lawsuit with Edwards Vacuum LLC and the potential impacts of geopolitical tensions and new regulations (like the BIOSECURE Act and Bulk Transfer Rule) add further headwinds. While the company is taking steps to remediate control issues and streamline its portfolio, the unresolved challenges warrant a cautious 'hold' stance. Investors should monitor the remediation of internal control weaknesses, the outcome of legal proceedings, and the successful divestiture of the B Medical Systems business before considering a more aggressive position.

Keywords

Life Sciences, Sample Management, Genomic Services, Automated Storage, Multiomics, Biotechnology, Pharmaceutical, SEC Filing, 10-K, Financial Results, Internal Controls, Cybersecurity, Supply Chain, AI, Intellectual Property, AZTA